Atlas Trials

Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer

Clinical trial NCT01033032 · COMPLETED

Trial details

NCT number
NCT01033032
Sponsor
SCRI Development Innovations, LLC
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Metastatic Breast Cancer
Start date
2009-12-01
Primary completion
2013-07-01
Enrollment
78

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.